Update on the treatment of metastatic squamous non-small cell lung cancer in new era of personalized medicine

Frontiers in Oncology

Volumn 7, Issue MAR, 2017, Pages

  Soldera, Sara Victoria ^a   Leighl, Natasha B ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Lung cancer; Molecular sequence data; Personalized medicine; Squamous cell carcinoma; Targeted therapy

Indexed keywords

AFATINIB; CABOZANTINIB; CETUXIMAB; CRIZOTINIB; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DISCOIDIN DOMAIN RECEPTOR 2; DOCETAXEL; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; GINSENOSIDE RB 1; IMMUNOGLOBULIN G1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MATUZUMAB; NECITUMUMAB; NIVOLUMAB; NOTCH1 RECEPTOR; ONARTUZUMAB; PANITUMUMAB; PEMBROLIZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PILARALISIB; PROTEIN TYROSINE KINASE INHIBITOR; RETINOBLASTOMA PROTEIN;

CANCER IMMUNOTHERAPY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); EPITHELIAL MESENCHYMAL TRANSITION; HLA SYSTEM; HUMAN; LUNG METASTASIS; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; SHORT SURVEY; SQUAMOUS CELL CARCINOMA;

EID: 85017161425     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2017.00050     Document Type: Short Survey

References (90)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer (2013). Available from: http://globocan.iarc.fr
2. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2013. Bethesda, MD: National Cancer Institute (2016). Available from: http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 350:2129-39. doi:10.1056/NEJMoa040938
4. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature (2007) 448:561-6. doi:10.1038/nature05945
5. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib monotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med (2010) 362:2380-8. doi:10.1056/NEJMoa0909530
6. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 13:239-44. doi:10.1016/S1470-2045(11)70393-X
7. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol (2013) 31:3327-34. doi:10.1200/JCO.2012.44.2806
8. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol (2014) 15:213-22. doi:10.1016/S1470-2045(13)70604-1
9. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 361:947-57. doi:10.1056/NEJMoa0810699
10. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol (2012) 30:1122-8. doi:10.1200/JCO.2011.36.8456
11. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 368:2385-94. doi:10.1056/NEJMoa1214886
12. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 370:1189-97. doi:10.1056/NEJMoa1311107
13. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol (2013) 8:823-59. doi:10.1097/JTO.0b013e318290868f
14. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 489:519-25. doi:10.1038/nature11404
15. Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, et al. Phosphoinositide 3-Kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res (2012) 18:6771-83. doi:10.1158/1078-0432.CCR-12-2347
16. Clinical Lung Cancer Genome Project (CLCGP), Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci Transl Med (2013) 5:209ra153. doi:10.1126/scitranslmed.3006802
17. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 2:62ra93. doi:10.1126/scitranslmed.3001451
18. Heist RS, Mino-Kenudson M, Sequist LV, Tammireddy S, Morrissey L, Christiani DC, et al. FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol (2012) 7:1775-80. doi:10.1097/JTO.0b013e31826aed28
19. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, et al. PI3KCA mutations and copy number gains in human lung cancers. Cancer Res (2008) 68:6913-21. doi:10.1158/0008-5472.CAN-07-5084
20. Kawano O, Sasaki H, Endo K, Suzuki E, Haneda H, Yukiue H, et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer (2006) 54:209-15. doi:10.1016/j.lungcan.2006.07.006
21. Jin G, Kim MJ, Jeon HS, Choi JE, Kim DS, Lee EB, et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer (2010) 69:279-83. doi:10.1016/j.lungcan.2009.11.012
22. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 1:78-89. doi:10.1158/2159-8274.CD-11-0005
23. Go H, Jeon YK, Park HJ, Sung SW, Seo JW, Chung DH. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol (2010) 5:305-13. doi:10.1097/JTO.0b013e3181ce3d1d
24. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature (2013) 500:415-21. doi:10.1038/nature12477
25. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med (2011) 32:605-44. doi:10.1016/j.ccm.2011.09.001
26. Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, Brahmer JR, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2015) 33:3488-515. doi:10.1200/JCO.2015.62.1342
27. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 466:869-73. doi:10.1038/nature09208
28. Shepherd FA, Pereira JR, Ciuleanu T, Ciuleanu T, Tan EH, Hirsh V, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 353:123-32. doi:10.1056/NEJMoa050753
29. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 372:1809-18. doi:10.1016/S0140-6736(08)61758-4
30. Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol (2015) 16:897-907. doi:10.1016/S1470-2045(15)00006-6
31. Lynch TJ, Patel T, Dreisbach L, McCleaod M, Heim WJ, Hermann RC, et al. Cetuximan and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol (2010) 28:911-7. doi:10.1200/JCO.2009.21.9618
32. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet (2009) 373:1525-31. doi:10.1016/S0140-6736(09)60569-9
33. Pujol JL, Pirker R, Lynch TJ, Butts CA, Rosell R, Shepherd FA, et al. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer (2014) 83:211-8. doi:10.1016/j.lungcan.2013.11.006
34. Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol (2015) 16:763-74. doi:10.1016/S1470-2045(15)00021-2
35. Schiller JH, von Pawel J, Schütt P, Ansari RH, Thomas M, Saleh M, et al. Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol (2010) 5:1977-85. doi:10.1097/JTO.0b013e3181f4a5c9
36. Crawford J, Swanson P, Schwarzenberger P, Sandler A, Prager D, Zhang K, et al. A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol (2013) 8:1510-8. doi:10.1097/JTO.0b013e3182a7d1da
37. Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol (2014) 15:143-55. doi:10.1016/S1470-2045(13)70586-2
38. Lim SH, Sun JM, Choi YL, Kim HR, Ahn S, Lee JY, et al. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: a single-arm, phase 2 study. Cancer (2016) 122:3024-31. doi:10.1002/cncr.30135
39. Paik PK, Shen R, Ferry D, Soria J-C, Mathewson A, Kilgour E, et al. Phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: preliminary antitumor activity and pharmacodynamics data. J Clin Oncol (2014) 32(Suppl; abstr 8035)
40. Nogova L, Sequist LV, Cassier PA, Hidalgo M, Delord J-P, Schuler MH, et al. Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398. J Clin Oncol (2014) 32(Suppl; abstr 8034)
41. Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol (2009) 20:1674-81. doi:10.1093/annonc/mdp060
42. Ramalingam SS, Owonikoko TK, Behera M, Subramanian J, Saba NF, Kono SA, et al. Phase II study of docetaxel in combination with everolimus for second-or third-line therapy of advanced non-small-cell lung cancer. J Thorac Oncol (2013) 8:369-72. doi:10.1097/JTO.0b013e318282709c
43. Besse B, Leighl N, Bennouna J, Papadimitrakopoulou VA, Blais N, Traynor AM, et al. Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. Ann Oncol (2014) 25:409-15. doi:10.1093/annonc/mdt536
44. Vansteenkiste JF, Canon JL, Braud FD, Grossi F, De Pas T, Gray JE, et al. Safety and efficacy of buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung cancer: results from the phase II BASALT-1 study. J Thorac Oncol (2015) 10:1319-27. doi:10.1097/JTO.0000000000000607
45. Levy B, Spira A, Becker D, Evans T, Schnadig I, Camidge DR, et al. A randomized, phase 2 trial of docetaxel with or without px-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer. J Thorac Oncol (2014) 9:1031-5. doi:10.1097/JTO.0000000000000183
46. Gopalan PK, Pinder MC, Chiappori A, Ivey AM, Villegas AG, Kaye FJ, et al. A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A. J Clin Oncol (2014) 32(Suppl; abstr 8077):5s
47. Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov (2016) 6:740-53. doi:10.1158/2159-8290.CD-16-0095
48. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, et al. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 28:4609-15. doi:10.1200/jco.2010.28.15_suppl.7594
49. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 28:1387-94. doi:10.1200/JCO.2009.25.4029
50. Hirsch FR, Govindan R, Zvirbule Z, Braiteh F, Rittmeyer A, Belda-Iniesta C, et al. Efficacy and safety results from a phase II, placebo-controlled study of onartuzumab plus first-line platinum-doublet chemotherapy for advanced squamous cell non-small-cell lung cancer. Clin Lung Cancer (2017) 18:43-9. doi:10.1016/j.cllc.2016.05.011
51. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol (2011) 29:3307-15. doi:10.1200/JCO.2010.34.0570
52. Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Shames DS, Yu W, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol (2014) 32(Suppl; abstr 8000)
53. Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH Jr, Blumenschein GR Jr, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 31:4105-14. doi:10.1200/JCO.2012.47.4189
54. Hirsch FR, Boyle TA, Thatcher N, Paz-Ares L, Varella-Garcia M, Kowalewski A, et al. EGFR IHC and FISH correlative analyses (SQUIRE trial): necitumumab + gemcitabine-cisplatin vs gemcitabine-cisplatin in 1st-line squamous NSCLC. 16th World Conference on Lung Cancer; Denver (2015). Sep 9. Abstract ORAL32.05
55. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol (2003) 21:3798-807. doi:10.1200/JCO.2003.11.069
56. Dacic S, Flanagan M, Cieply K, Ramalingam S, Luketich J, Belani C, et al. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol (2006) 125:860-5. doi:10.1309/H5UW6CPCWWC92241
57. López-Malpartida AV, Ludeña MD, Varela G, García Pichel J. Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas. Lung Cancer (2009) 65:25-33. doi:10.1016/j.lungcan.2008.10.009
58. Uramoto H, Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer (2007) 96:857-63. doi:10.1038/sj.bjc.6603665
59. Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol (2014) 25:552-63. doi:10.1093/annonc/mdt419
60. Lewin J, Siu LL. Development of fibroblast growth factor receptor inhibitors: kissing frogs to find a prince? J Clin Oncol (2015) 33:3372-4. doi:10.1200/JCO.2015.62.7380
61. Salgia R. Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors. Cancer Med (2014) 3:681-92. doi:10.1002/cam4.238
62. Bono F, De Smet F, Herbert C, De Bock K, Georgiadou M, Fons P, et al. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell (2013) 23:477-88. doi:10.1016/j.ccr.2013.02.019
63. Kim HR, Kim DJ, Kang DR, Lee JG, Lim SM, Lee CY, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol (2013) 31:731-7. doi:10.1200/JCO.2012.43.8622
64. Soria JC, DeBraud F, Bahleda R, Adamo B, Andre F, Dienstmann R, et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol (2014) 25:2244-51. doi:10.1093/annonc/mdu390
65. Papadimitrakopoulou V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol (2012) 7:1315-26. doi:10.1097/JTO.0b013e31825493eb
66. Cantley LC. The phosphoinositide 3-kinase pathway. Science (2002) 296:1655-7. doi:10.1126/science.296.5573.1655
67. Bonelli MA, Cavazzoni A, Saccani F, Alfieri RR, Quaini F, La Monica S, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. Mol Cancer Ther (2015) 14:1916-27. doi:10.1158/1535-7163.MCT-14-0892
68. Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B (2015) 5:390-401. doi:10.1016/j.apsb.2015.07.001
69. Soria JC, LoRusso P, Bahleda R, Lager J, Liu L, Jiang J, et al. Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors. Oncologist (2015) 20:245-6. doi:10.1634/theoncologist.2014-0449
70. Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Braña I, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2014) 20:233-45. doi:10.1158/1078-0432.CCR-13-1777
71. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov (2015) 14:130-46. doi:10.1038/nrd4504
72. Ohtani N, Yamakoshi K, Takahashi A, Hara E. The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. J Med Invest (2014) 51:146-53. doi:10.2152/jmi.51.146
73. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY. D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol (1994) 14:2066-76. doi:10.1128/MCB.14.3.2066
74. Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov (2016) 6:353-67. doi:10.1158/2159-8290.CD-15-0894
75. Leitinger B. Molecular analysis of collagen binding by the human discoidin domain receptors, DDR1 and DDR2 identification of collagen binding sites in DDR2. J Biol Chem (2003) 278:16761-9. doi:10.1074/jbc.M301370200
76. Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharamacol (2008) 599:44-53. doi:10.1016/j.ejphar.2008.10.014
77. Pitini V, Arrigo C, Di Mirto C, Mondello P, Altavilla G. Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. Lung Cancer (2013) 82:171-2. doi:10.1016/j.lungcan.2013.07.004
78. Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. J Clin Oncol (2013) 31:1089-96. doi:10.1200/JCO.2012.43.9422
79. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 4:915-25. doi:10.1038/nrm1261
80. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 316:1039-43. doi:10.1126/science.1141478
81. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 6:942-6. doi:10.1097/JTO.0b013e31821528d3
82. Paik PK, Drilon A, Fan P, Yu H, Rekhtman N, Ginsberg MS, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cacner Discov (2015) 5:842-9. doi:10.1158/2159-8290.CD-14-1467
83. Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, et al. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol (2015) 33:2667-74. doi:10.1200/JCO.2014.60.7317
84. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med (2015) 373:123-35. doi:10.1056/NEJMoa1504627
85. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med (2015) 373:1627-39. doi:10.1056/NEJMoa1507643
86. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (2016) 387:1540-50. doi:10.1016/S0140-6736(15)01281-7
87. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet (2016) 387:1837-46. doi:10.1016/S0140-6736(16)00587-0
88. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med (2016) 375:1823-33. doi:10.1056/NEJMoa1606774
89. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 1:44-53. doi:10.1158/2159-8274.CD-10-0010
90. Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, et al. Lung master protocol (Lung-MAP)-a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res (2015) 21:1514-24. doi:10.1158/1078-0432.CCR-13-3473